Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome

This study has been completed.
Information provided by:
Astellas Pharma Inc Identifier:
First received: September 13, 2005
Last updated: October 18, 2007
Last verified: October 2007
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.

Condition Intervention Phase
Urinary Tract Diseases
Drug: Tamuslosin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:


Ages Eligible for Study:   20 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs).

Exclusion Criteria:

  • Patients with urination disorder accompanied by apparent organic or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00239265

Chubu region, Japan
Chugoku region, Japan
Hokkaido region, Japan
Kinki region, Japan
Kyushu region, Japan
Touhoku region, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Study Chair: Study Director Clinical Development, Astellas Pharma Inc.
  More Information Identifier: NCT00239265     History of Changes
Other Study ID Numbers: B6171/LCT2
Study First Received: September 13, 2005
Last Updated: October 18, 2007

Keywords provided by Astellas Pharma Inc:
urinary tract diseases

Additional relevant MeSH terms:
Urologic Diseases
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on April 27, 2017